[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 2 days · First seen · Last updated

Ardent Health earnings guidance and results

Overview

On 3 August 2026, Ardent Health (NYSE: ARDT) issued its fiscal‑year‑2026 outlook, forecasting earnings per share of $0.78‑$1.15 and revenue of $6.4‑$6.7 billion, both below analyst consensus. The company’s shares were trading near $10.74.

The following day, 4 August 2026, the firm reported its quarterly results, posting EPS of $0.12, which missed the $0.18 consensus estimate, and revenue of $1.62 billion, slightly above expectations. Net margin was 2.09% and return on equity 13.85%. Ardent reaffirmed its FY 2026 EPS guidance range of $0.78‑$1.15, and the stock remained around $10.74. Institutional investors, including First Trust Advisors and several banks, increased their holdings during the quarter.

Entities

Aptiv · Andreas Bechtolsheim · Arista Networks Inc. · First Trust Advisors LP · Arcutis Biotherapeutics Inc.

Timeline

  1. 19 days ago

    [BUSINESS] 2 sources
    Arcutis Biotherapeutics insider sale and Arista Networks receives $3.6M investment

    Arcutis Biotherapeutics posted strong earnings and insiders sold shares, while Arista Networks attracted a $3.6 M investment from Mirador Capital and saw insider sales by Andreas Bechtolsheim.

  2. 20 days ago

    [BUSINESS] 2 sources
    Ardent Health Issues FY 2026 Guidance; Aptiv Reports Q2 Results

    Ardent Health set FY‑2026 EPS at $0.78‑$1.15 and revenue $6.4‑$6.7 B, below forecasts; Aptiv posted Q2 revenue $3.3 B, EPS $1.63, citing weak China demand and growth in non‑automotive segments.

Sources

mommygearest.com · stocknews.com